Trials / Unknown
UnknownNCT00054496
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
Detailed description
OBJECTIVES: * Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib. * Determine the progression-free and overall survival of patients treated with this drug. OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib hydrochloride |
Timeline
- Start date
- 2002-08-01
- First posted
- 2003-02-06
- Last updated
- 2014-01-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00054496. Inclusion in this directory is not an endorsement.